The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
MYM Nutraceuticals Featured in Midas Letter Article
May. 10, 2018 09:40AM PST
Cannabis Investing News
MYM Nutraceuticals Inc. (CSE:MYM) was recently featured in an article by Midas Letter that highlighted several small cap cannabis companies that are well positioned in the sector.
MYM Nutraceuticals Inc. (CSE:MYM) was recently featured in an article by Midas Letter that highlighted several small cap cannabis companies that are well positioned in the sector.
As quoted in the article, MYM Nutraceuticals:
Provided an update regarding their Sublime Culture Inc. ACMPR production facility located in Laval, Quebec. MYM reaffirmed the Sublime Culture ACMPR license application is currently in queue awaiting final review from Health Canada. The company further confirmed it was satisfied that is “has provided Health Canada with all the necessary information in order for them to move ahead with the license application.”
MYM Nutraceuticals had previously submitted a Confirmation of Readiness (COR) for licensing to Health Canada on December 15, 2017. Phase two of the project in Laval would see grow capacity almost quadruple, from 10,000 ft2 to 37,000 ft2.
Turns out, the corporate update was exact panacea MYM Nutraceuticals needed to turn around their stock price.
Click here to read the full article.
Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.